nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—HTR2B—Sorafenib—liver cancer	0.38	0.476	CbGbCtD
Agomelatine—HTR2C—Sorafenib—liver cancer	0.248	0.31	CbGbCtD
Agomelatine—CYP1A2—Sorafenib—liver cancer	0.0901	0.113	CbGbCtD
Agomelatine—CYP2C9—Sorafenib—liver cancer	0.0812	0.102	CbGbCtD
Agomelatine—Indomethacin—PPARA—liver cancer	0.00322	0.377	CrCbGaD
Agomelatine—Eczema—Sorafenib—liver cancer	0.00229	0.0281	CcSEcCtD
Agomelatine—Hepatic failure—Sorafenib—liver cancer	0.00229	0.0281	CcSEcCtD
Agomelatine—Nasopharyngitis—Sorafenib—liver cancer	0.00184	0.0226	CcSEcCtD
Agomelatine—Weight decreased—Sorafenib—liver cancer	0.00161	0.0198	CcSEcCtD
Agomelatine—Infestation—Sorafenib—liver cancer	0.00159	0.0195	CcSEcCtD
Agomelatine—Infestation NOS—Sorafenib—liver cancer	0.00159	0.0195	CcSEcCtD
Agomelatine—Jaundice—Sorafenib—liver cancer	0.00155	0.019	CcSEcCtD
Agomelatine—Indomethacin—PPARG—liver cancer	0.00154	0.18	CrCbGaD
Agomelatine—Hepatobiliary disease—Sorafenib—liver cancer	0.0015	0.0184	CcSEcCtD
Agomelatine—Connective tissue disorder—Sorafenib—liver cancer	0.0014	0.0172	CcSEcCtD
Agomelatine—Melatonin—ESR1—liver cancer	0.00138	0.162	CrCbGaD
Agomelatine—Rash erythematous—Epirubicin—liver cancer	0.00137	0.0168	CcSEcCtD
Agomelatine—Tinnitus—Sorafenib—liver cancer	0.00133	0.0163	CcSEcCtD
Agomelatine—Rash erythematous—Doxorubicin—liver cancer	0.00127	0.0156	CcSEcCtD
Agomelatine—Mental disorder—Sorafenib—liver cancer	0.00125	0.0153	CcSEcCtD
Agomelatine—Angioedema—Sorafenib—liver cancer	0.00113	0.0139	CcSEcCtD
Agomelatine—Melatonin—CYP1A1—liver cancer	0.00111	0.129	CrCbGaD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00105	0.0129	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Epirubicin—liver cancer	0.00105	0.0129	CcSEcCtD
Agomelatine—Abnormal dreams—Epirubicin—liver cancer	0.00104	0.0127	CcSEcCtD
Agomelatine—Dry mouth—Sorafenib—liver cancer	0.00103	0.0127	CcSEcCtD
Agomelatine—Infection—Sorafenib—liver cancer	0.00101	0.0124	CcSEcCtD
Agomelatine—Nervous system disorder—Sorafenib—liver cancer	0.000994	0.0122	CcSEcCtD
Agomelatine—Skin disorder—Sorafenib—liver cancer	0.000985	0.0121	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000972	0.0119	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—liver cancer	0.00096	0.0118	CcSEcCtD
Agomelatine—Dyspepsia—Sorafenib—liver cancer	0.000892	0.0109	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000876	0.0107	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Sorafenib—liver cancer	0.000875	0.0107	CcSEcCtD
Agomelatine—Fatigue—Sorafenib—liver cancer	0.000874	0.0107	CcSEcCtD
Agomelatine—Constipation—Sorafenib—liver cancer	0.000867	0.0106	CcSEcCtD
Agomelatine—Eczema—Epirubicin—liver cancer	0.000848	0.0104	CcSEcCtD
Agomelatine—Hepatic failure—Epirubicin—liver cancer	0.000848	0.0104	CcSEcCtD
Agomelatine—Gastrointestinal pain—Sorafenib—liver cancer	0.000829	0.0102	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000811	0.00994	CcSEcCtD
Agomelatine—Urticaria—Sorafenib—liver cancer	0.000805	0.00988	CcSEcCtD
Agomelatine—Abdominal pain—Sorafenib—liver cancer	0.000801	0.00983	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—liver cancer	0.000785	0.00962	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—liver cancer	0.000785	0.00962	CcSEcCtD
Agomelatine—Migraine—Epirubicin—liver cancer	0.00075	0.0092	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—liver cancer	0.000736	0.00902	CcSEcCtD
Agomelatine—Asthenia—Sorafenib—liver cancer	0.000727	0.00892	CcSEcCtD
Agomelatine—Pruritus—Sorafenib—liver cancer	0.000717	0.0088	CcSEcCtD
Agomelatine—Naproxen—ALB—liver cancer	0.000715	0.0837	CrCbGaD
Agomelatine—Migraine—Doxorubicin—liver cancer	0.000694	0.00851	CcSEcCtD
Agomelatine—Diarrhoea—Sorafenib—liver cancer	0.000694	0.00851	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—liver cancer	0.000682	0.00836	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—liver cancer	0.000681	0.00835	CcSEcCtD
Agomelatine—Dizziness—Sorafenib—liver cancer	0.00067	0.00822	CcSEcCtD
Agomelatine—Influenza—Epirubicin—liver cancer	0.000659	0.00808	CcSEcCtD
Agomelatine—Vomiting—Sorafenib—liver cancer	0.000645	0.0079	CcSEcCtD
Agomelatine—Headache—Sorafenib—liver cancer	0.000635	0.00779	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—liver cancer	0.000631	0.00773	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—liver cancer	0.00061	0.00748	CcSEcCtD
Agomelatine—Nausea—Sorafenib—liver cancer	0.000602	0.00738	CcSEcCtD
Agomelatine—Weight increased—Epirubicin—liver cancer	0.0006	0.00735	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—liver cancer	0.000596	0.00731	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—liver cancer	0.000587	0.0072	CcSEcCtD
Agomelatine—Infestation—Epirubicin—liver cancer	0.000587	0.0072	CcSEcCtD
Agomelatine—Indomethacin—ALB—liver cancer	0.00058	0.0679	CrCbGaD
Agomelatine—Jaundice—Epirubicin—liver cancer	0.000573	0.00702	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—liver cancer	0.000556	0.00681	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—liver cancer	0.000555	0.0068	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—liver cancer	0.000551	0.00676	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—liver cancer	0.000543	0.00667	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—liver cancer	0.000543	0.00667	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—liver cancer	0.00053	0.0065	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—liver cancer	0.000527	0.00647	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—liver cancer	0.000518	0.00635	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—liver cancer	0.000514	0.0063	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—liver cancer	0.000493	0.00604	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—liver cancer	0.000492	0.00603	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—liver cancer	0.000488	0.00598	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—liver cancer	0.000479	0.00588	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—liver cancer	0.000462	0.00567	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—liver cancer	0.000456	0.00559	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—liver cancer	0.000455	0.00558	CcSEcCtD
Agomelatine—Back pain—Epirubicin—liver cancer	0.000444	0.00545	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—liver cancer	0.000433	0.00531	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—liver cancer	0.000427	0.00524	CcSEcCtD
Agomelatine—Agitation—Epirubicin—liver cancer	0.000422	0.00517	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—liver cancer	0.000412	0.00506	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—liver cancer	0.000411	0.00504	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—liver cancer	0.0004	0.00491	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—liver cancer	0.00039	0.00479	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—liver cancer	0.000389	0.00478	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000388	0.00476	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—liver cancer	0.000382	0.00469	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—liver cancer	0.000382	0.00468	CcSEcCtD
Agomelatine—Infection—Epirubicin—liver cancer	0.000372	0.00456	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—liver cancer	0.000367	0.00451	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—liver cancer	0.000364	0.00446	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—liver cancer	0.000362	0.00444	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—liver cancer	0.00036	0.00442	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000359	0.0044	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—liver cancer	0.000354	0.00434	CcSEcCtD
Agomelatine—Infection—Doxorubicin—liver cancer	0.000344	0.00422	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—liver cancer	0.00034	0.00417	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—liver cancer	0.000339	0.00416	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—liver cancer	0.000337	0.00413	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—liver cancer	0.000336	0.00413	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—liver cancer	0.000335	0.00411	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—liver cancer	0.000333	0.00408	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—liver cancer	0.00033	0.00404	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000323	0.00397	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—liver cancer	0.000323	0.00396	CcSEcCtD
Agomelatine—Constipation—Epirubicin—liver cancer	0.00032	0.00393	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—liver cancer	0.000314	0.00384	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—liver cancer	0.000311	0.00382	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—liver cancer	0.000308	0.00378	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—liver cancer	0.000306	0.00376	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—liver cancer	0.000305	0.00374	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000299	0.00367	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—liver cancer	0.000299	0.00367	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—liver cancer	0.000298	0.00365	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—liver cancer	0.000296	0.00364	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—liver cancer	0.000296	0.00363	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000283	0.00348	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—liver cancer	0.000275	0.00338	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—liver cancer	0.000274	0.00336	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—liver cancer	0.000269	0.0033	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—liver cancer	0.000265	0.00325	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—liver cancer	0.000256	0.00314	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—liver cancer	0.000249	0.00305	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—liver cancer	0.000248	0.00304	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—liver cancer	0.000245	0.00301	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—liver cancer	0.000238	0.00292	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—liver cancer	0.000237	0.00291	CcSEcCtD
Agomelatine—Headache—Epirubicin—liver cancer	0.000235	0.00288	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—liver cancer	0.000229	0.00281	CcSEcCtD
Agomelatine—Nausea—Epirubicin—liver cancer	0.000223	0.00273	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—liver cancer	0.00022	0.0027	CcSEcCtD
Agomelatine—Headache—Doxorubicin—liver cancer	0.000217	0.00266	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—liver cancer	0.000206	0.00253	CcSEcCtD
Agomelatine—HTR2B—Signaling by GPCR—CSF2—liver cancer	5.92e-05	0.000534	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CDKN1B—liver cancer	5.85e-05	0.000528	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CDKN1B—liver cancer	5.85e-05	0.000528	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—EPT1—liver cancer	5.8e-05	0.000524	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	5.79e-05	0.000523	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—AKT1—liver cancer	5.78e-05	0.000522	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—AKT1—liver cancer	5.78e-05	0.000522	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TRIO—liver cancer	5.77e-05	0.000522	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CASP3—liver cancer	5.73e-05	0.000518	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CASP3—liver cancer	5.73e-05	0.000518	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL2—liver cancer	5.72e-05	0.000517	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL2—liver cancer	5.72e-05	0.000517	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL6—liver cancer	5.69e-05	0.000514	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL6—liver cancer	5.69e-05	0.000514	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—liver cancer	5.58e-05	0.000504	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—liver cancer	5.58e-05	0.000504	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—JUN—liver cancer	5.56e-05	0.000503	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—JUN—liver cancer	5.56e-05	0.000503	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCR4—liver cancer	5.53e-05	0.0005	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CTNNB1—liver cancer	5.52e-05	0.000499	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CTNNB1—liver cancer	5.52e-05	0.000499	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TAT—liver cancer	5.5e-05	0.000496	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ADAM17—liver cancer	5.42e-05	0.00049	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MMP9—liver cancer	5.41e-05	0.000489	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MMP9—liver cancer	5.41e-05	0.000489	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	5.41e-05	0.000488	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PRKCE—liver cancer	5.39e-05	0.000487	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CDKN1A—liver cancer	5.39e-05	0.000487	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CDKN1A—liver cancer	5.39e-05	0.000487	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	5.35e-05	0.000484	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK8—liver cancer	5.27e-05	0.000476	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK8—liver cancer	5.27e-05	0.000476	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CSF2—liver cancer	5.26e-05	0.000475	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—AKT1—liver cancer	5.25e-05	0.000474	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—AKT1—liver cancer	5.25e-05	0.000474	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	5.12e-05	0.000463	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—F2—liver cancer	5.11e-05	0.000462	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PSMD10—liver cancer	5.1e-05	0.000461	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PSMA4—liver cancer	5.1e-05	0.000461	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CG—liver cancer	4.89e-05	0.000442	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—liver cancer	4.86e-05	0.000439	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—liver cancer	4.86e-05	0.000439	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—STAT3—liver cancer	4.81e-05	0.000435	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—STAT3—liver cancer	4.81e-05	0.000435	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CSF2—liver cancer	4.77e-05	0.000431	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4.73e-05	0.000428	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—F2—liver cancer	4.64e-05	0.000419	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MYC—liver cancer	4.47e-05	0.000404	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MYC—liver cancer	4.47e-05	0.000404	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TGFB1—liver cancer	4.46e-05	0.000403	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TGFB1—liver cancer	4.46e-05	0.000403	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CG—liver cancer	4.44e-05	0.000401	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ADAM17—liver cancer	4.38e-05	0.000395	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GLUL—liver cancer	4.37e-05	0.000395	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CPT1B—liver cancer	4.37e-05	0.000395	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CD—liver cancer	4.3e-05	0.000389	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NR1H4—liver cancer	4.22e-05	0.000381	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTA3—liver cancer	4.14e-05	0.000374	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—liver cancer	4.13e-05	0.000373	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—liver cancer	4.13e-05	0.000373	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—F2—liver cancer	4.12e-05	0.000373	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PSMA4—liver cancer	4.11e-05	0.000372	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PSMD10—liver cancer	4.11e-05	0.000372	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4.05e-05	0.000365	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PRKCE—liver cancer	3.95e-05	0.000357	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CG—liver cancer	3.95e-05	0.000357	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CD—liver cancer	3.91e-05	0.000353	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CA—liver cancer	3.8e-05	0.000343	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CA—liver cancer	3.8e-05	0.000343	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTA4—liver cancer	3.79e-05	0.000342	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CB—liver cancer	3.75e-05	0.000339	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—F2—liver cancer	3.75e-05	0.000338	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF2—liver cancer	3.74e-05	0.000338	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GLUL—liver cancer	3.74e-05	0.000337	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CPT1B—liver cancer	3.74e-05	0.000337	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.7e-05	0.000335	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTA2—liver cancer	3.69e-05	0.000334	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—liver cancer	3.67e-05	0.000332	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—liver cancer	3.67e-05	0.000332	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NR1H4—liver cancer	3.6e-05	0.000325	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CG—liver cancer	3.58e-05	0.000324	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTA1—liver cancer	3.56e-05	0.000322	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTA3—liver cancer	3.54e-05	0.00032	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NAT2—liver cancer	3.52e-05	0.000318	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—liver cancer	3.51e-05	0.000317	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—liver cancer	3.51e-05	0.000317	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CSF2—liver cancer	3.49e-05	0.000316	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—RAF1—liver cancer	3.49e-05	0.000315	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CD—liver cancer	3.47e-05	0.000313	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—H2AFX—liver cancer	3.44e-05	0.000311	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—IL2—liver cancer	3.44e-05	0.000311	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CB—liver cancer	3.4e-05	0.000308	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.39e-05	0.000306	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALDOB—liver cancer	3.38e-05	0.000305	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL6—liver cancer	3.36e-05	0.000304	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL6—liver cancer	3.36e-05	0.000304	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTA4—liver cancer	3.24e-05	0.000293	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CRABP1—liver cancer	3.22e-05	0.000291	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PRKCE—liver cancer	3.19e-05	0.000288	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.17e-05	0.000286	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTA2—liver cancer	3.16e-05	0.000285	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CD—liver cancer	3.15e-05	0.000285	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—liver cancer	3.13e-05	0.000282	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—liver cancer	3.11e-05	0.000281	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—liver cancer	3.1e-05	0.00028	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—liver cancer	3.1e-05	0.00028	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTA1—liver cancer	3.05e-05	0.000275	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CB—liver cancer	3.02e-05	0.000273	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF2—liver cancer	3.02e-05	0.000273	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NAT2—liver cancer	3.01e-05	0.000272	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.9e-05	0.000262	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.9e-05	0.000262	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALDOB—liver cancer	2.89e-05	0.000261	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KDR—liver cancer	2.85e-05	0.000257	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK14—liver cancer	2.83e-05	0.000256	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CSF2—liver cancer	2.82e-05	0.000255	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HPGDS—liver cancer	2.82e-05	0.000254	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—RAF1—liver cancer	2.81e-05	0.000254	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.8e-05	0.000253	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—H2AFX—liver cancer	2.78e-05	0.000251	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—liver cancer	2.78e-05	0.000251	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ESR1—liver cancer	2.78e-05	0.000251	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CRABP1—liver cancer	2.75e-05	0.000249	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CB—liver cancer	2.75e-05	0.000248	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—F2—liver cancer	2.74e-05	0.000248	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APC—liver cancer	2.62e-05	0.000237	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CG—liver cancer	2.62e-05	0.000237	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.55e-05	0.00023	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—liver cancer	2.52e-05	0.000228	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.52e-05	0.000228	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—liver cancer	2.51e-05	0.000227	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PSMA4—liver cancer	2.51e-05	0.000227	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PSMD10—liver cancer	2.51e-05	0.000227	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.48e-05	0.000224	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BRAF—liver cancer	2.47e-05	0.000223	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GOT2—liver cancer	2.44e-05	0.000221	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HPGDS—liver cancer	2.41e-05	0.000217	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.39e-05	0.000216	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CD—liver cancer	2.31e-05	0.000208	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KDR—liver cancer	2.3e-05	0.000208	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP2E1—liver cancer	2.3e-05	0.000207	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—liver cancer	2.29e-05	0.000206	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK14—liver cancer	2.28e-05	0.000206	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SERPINE1—liver cancer	2.28e-05	0.000206	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—liver cancer	2.26e-05	0.000204	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ESR1—liver cancer	2.24e-05	0.000202	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.22e-05	0.000201	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—F2—liver cancer	2.21e-05	0.0002	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.18e-05	0.000197	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.15e-05	0.000194	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYCS—liver cancer	2.15e-05	0.000194	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PSMA4—liver cancer	2.15e-05	0.000194	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PSMD10—liver cancer	2.15e-05	0.000194	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APC—liver cancer	2.12e-05	0.000191	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CG—liver cancer	2.12e-05	0.000191	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GGT1—liver cancer	2.11e-05	0.00019	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GOT1—liver cancer	2.11e-05	0.00019	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GOT2—liver cancer	2.09e-05	0.000189	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—liver cancer	2.08e-05	0.000187	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RAF1—liver cancer	2.06e-05	0.000186	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MTOR—liver cancer	2.01e-05	0.000182	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CB—liver cancer	2.01e-05	0.000182	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BRAF—liver cancer	1.99e-05	0.00018	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2E1—liver cancer	1.96e-05	0.000177	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—liver cancer	1.92e-05	0.000173	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.9e-05	0.000172	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTP1—liver cancer	1.89e-05	0.000171	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1B—liver cancer	1.89e-05	0.00017	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HMOX1—liver cancer	1.87e-05	0.000169	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—liver cancer	1.87e-05	0.000169	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CD—liver cancer	1.86e-05	0.000168	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—liver cancer	1.85e-05	0.000167	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—liver cancer	1.85e-05	0.000167	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—liver cancer	1.84e-05	0.000167	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SERPINE1—liver cancer	1.84e-05	0.000166	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—liver cancer	1.84e-05	0.000166	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYCS—liver cancer	1.84e-05	0.000166	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—liver cancer	1.82e-05	0.000165	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GGT1—liver cancer	1.8e-05	0.000163	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GOT1—liver cancer	1.8e-05	0.000163	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—liver cancer	1.8e-05	0.000163	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JUN—liver cancer	1.8e-05	0.000162	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNB1—liver cancer	1.78e-05	0.000161	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MMP9—liver cancer	1.75e-05	0.000158	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1A—liver cancer	1.74e-05	0.000157	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—liver cancer	1.74e-05	0.000157	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK8—liver cancer	1.7e-05	0.000154	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—liver cancer	1.7e-05	0.000153	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	1.67e-05	0.000151	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RAF1—liver cancer	1.66e-05	0.00015	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1A1—liver cancer	1.65e-05	0.000149	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CB—liver cancer	1.62e-05	0.000147	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MTOR—liver cancer	1.62e-05	0.000147	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTP1—liver cancer	1.62e-05	0.000146	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HMOX1—liver cancer	1.6e-05	0.000144	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—liver cancer	1.57e-05	0.000142	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—liver cancer	1.55e-05	0.00014	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—liver cancer	1.55e-05	0.00014	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTHFR—liver cancer	1.54e-05	0.000139	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1B—liver cancer	1.52e-05	0.000138	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARA—liver cancer	1.51e-05	0.000136	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—liver cancer	1.51e-05	0.000136	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—liver cancer	1.49e-05	0.000135	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—liver cancer	1.49e-05	0.000135	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—liver cancer	1.49e-05	0.000134	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—liver cancer	1.48e-05	0.000134	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—liver cancer	1.45e-05	0.000131	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JUN—liver cancer	1.45e-05	0.000131	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—liver cancer	1.44e-05	0.00013	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TGFB1—liver cancer	1.44e-05	0.00013	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.44e-05	0.00013	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MMP9—liver cancer	1.41e-05	0.000127	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1A1—liver cancer	1.41e-05	0.000127	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.41e-05	0.000127	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.37e-05	0.000124	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.37e-05	0.000124	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.36e-05	0.000122	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—liver cancer	1.33e-05	0.000121	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTHFR—liver cancer	1.31e-05	0.000119	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CG—liver cancer	1.29e-05	0.000117	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARA—liver cancer	1.29e-05	0.000116	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.27e-05	0.000114	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—liver cancer	1.25e-05	0.000113	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARG—liver cancer	1.25e-05	0.000113	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—liver cancer	1.23e-05	0.000111	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—liver cancer	1.19e-05	0.000107	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—liver cancer	1.16e-05	0.000105	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.16e-05	0.000105	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.16e-05	0.000105	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CD—liver cancer	1.14e-05	0.000103	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—liver cancer	1.13e-05	0.000102	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALB—liver cancer	1.12e-05	0.000101	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CG—liver cancer	1.1e-05	9.98e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—liver cancer	1.09e-05	9.81e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—liver cancer	1.08e-05	9.73e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARG—liver cancer	1.07e-05	9.63e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—liver cancer	1e-05	9.05e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CB—liver cancer	9.9e-06	8.95e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	9.89e-06	8.93e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CD—liver cancer	9.71e-06	8.77e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALB—liver cancer	9.58e-06	8.66e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—liver cancer	9.57e-06	8.64e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—liver cancer	9.15e-06	8.27e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—liver cancer	8.76e-06	7.91e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CB—liver cancer	8.46e-06	7.64e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—liver cancer	8.08e-06	7.3e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—liver cancer	6.04e-06	5.45e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—liver cancer	5.16e-06	4.66e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—liver cancer	4.93e-06	4.45e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—liver cancer	4.21e-06	3.81e-05	CbGpPWpGaD
